Cascadian Therapeutics Announces Poster Presentations on Tucatinib in Multiple Tumor Types at the European Society for Medical Oncology (ESMO) 2017 Congress
August 28, 2017 08:30 ET
|
Cascadian Therapeutics, Inc.
SEATTLE, Aug. 28, 2017 (GLOBE NEWSWIRE) -- Cascadian Therapeutics, Inc. (NASDAQ:CASC), a clinical-stage biopharmaceutical company, today announced posters on tucatinib in multiple tumor types will...
Cascadian Therapeutics Reports Second Quarter 2017 Financial Results
August 08, 2017 16:01 ET
|
Cascadian Therapeutics, Inc.
First Patients Randomized in Western Europe and Australia in Ongoing Global HER2CLIMB Registrational Trial of Tucatinib Conference Call Scheduled for Today at 4:30 p.m. ET SEATTLE, Aug. 08, 2017 ...
Cascadian Therapeutics to Report Second Quarter 2017 Financial Results on August 8, 2017
August 01, 2017 08:30 ET
|
Cascadian Therapeutics, Inc.
SEATTLE, Aug. 01, 2017 (GLOBE NEWSWIRE) -- Cascadian Therapeutics, Inc. (NASDAQ:CASC), a clinical-stage biopharmaceutical company, today announced that it will report its second quarter financial...
Cascadian Therapeutics Announces Positive Regulatory Update for Tucatinib in Europe
July 11, 2017 08:00 ET
|
Cascadian Therapeutics, Inc.
SEATTLE, July 11, 2017 (GLOBE NEWSWIRE) -- Cascadian Therapeutics, Inc. (NASDAQ:CASC), a clinical-stage biopharmaceutical company, today announced the outcome of discussions with the European...
Cascadian Therapeutics’ Lead Candidate, Tucatinib, Receives Orphan Drug Designation from FDA for Treatment of Breast Cancer Patients with Brain Metastases
June 08, 2017 08:00 ET
|
Cascadian Therapeutics, Inc.
SEATTLE, June 08, 2017 (GLOBE NEWSWIRE) -- Cascadian Therapeutics, Inc. (NASDAQ:CASC), a clinical-stage biopharmaceutical company, today announced that tucatinib, an investigational oral, small...
Cascadian Therapeutics to Present at Jefferies 2017 Healthcare Conference
May 31, 2017 08:30 ET
|
Cascadian Therapeutics, Inc.
SEATTLE, May 31, 2017 (GLOBE NEWSWIRE) -- Cascadian Therapeutics, Inc. (NASDAQ:CASC), a clinical-stage biopharmaceutical company, today announced that management will present at the Jefferies 2017...
Cascadian Therapeutics Reports First Quarter 2017 Financial Results Conference Call Scheduled for Today at 8:30 a.m. ET
May 09, 2017 07:00 ET
|
Cascadian Therapeutics, Inc.
SEATTLE, May 09, 2017 (GLOBE NEWSWIRE) -- Cascadian Therapeutics, Inc. (NASDAQ:CASC), a clinical-stage biopharmaceutical company, today reported financial results for the first quarter ended March...
Cascadian Therapeutics to Report First Quarter 2017 Financial Results on May 9, 2017
May 01, 2017 08:56 ET
|
Cascadian Therapeutics, Inc.
SEATTLE, May 01, 2017 (GLOBE NEWSWIRE) -- Cascadian Therapeutics, Inc. (NASDAQ:CASC), a clinical-stage biopharmaceutical company, today announced that it will report its financial results for the...
Cascadian Therapeutics Highlights Preclinical Program Presentations at the American Association for Cancer Research Annual Meeting 2017
April 05, 2017 08:00 ET
|
Cascadian Therapeutics, Inc.
SEATTLE, April 05, 2017 (GLOBE NEWSWIRE) -- Cascadian Therapeutics, Inc. (NASDAQ:CASC), a clinical-stage biopharmaceutical company, today announced data highlights from presentations of preclinical...
Cascadian Therapeutics Announces Changes to Board of Directors
March 13, 2017 16:01 ET
|
Cascadian Therapeutics, Inc.
SEATTLE, March 13, 2017 (GLOBE NEWSWIRE) -- Cascadian Therapeutics, Inc. (NASDAQ:CASC), a clinical-stage biopharmaceutical company, today announced that Robert W. Azelby has been appointed to the...